Nano-X Imaging reported Q2 2026 revenues of $4.2 million, up 37% year-over-year, driven by the consolidation of Nanox Health IT which contributed $0.9 million. The company recorded a $40.7 million non-cash impairment charge on AI solutions intangible assets, resulting in a GAAP net loss of $55.5 million compared to $14.7 million in Q2 2025. Cash and cash equivalents declined to $31.4 million from $60.0 million at year-end. Post-quarter, the company raised $8.5 million through a registered-direct offering and ATM program. Additionally, Nano-X announced a restructuring of its South Korea operations involving a 67% workforce reduction to generate approximately $2 million in annual cost savings starting in 2027. A class action securities lawsuit was filed on June 12, 2026, with no accrual recorded due to the early stage of proceedings. Nano-X Imaging operates in the medical imaging technology industry, providing digital X-ray hardware, AI-based diagnostic solutions, and teleradiology services.

Nano-X Imaging Ltd. announced its 2026 Annual General Meeting scheduled for September 17, 2026. The meeting agenda includes the re-election of directors Dan Suesskind and Michael Jackman to Class III board seats, the approval of an amendment to increase authorized share capital by 50,000,000 ordinary shares (par value NIS 0.01), bringing total authorized shares to 150,000,000, and the approval of two equity grants to CEO Erez Meltzer. The filing also notes the re-appointment of Kesselman & Kesselman as independent auditors for fiscal year 2026. Nano-X Imaging Ltd. operates in the medical technology industry, developing portable digital X-ray systems.

On August 7, 2026, Nano-X Imaging Ltd. completed a registered direct offering to a single long-term institutional investor, selling 8,000,000 ordinary shares (or pre-funded warrants) alongside 8,000,000 accompanying ordinary warrants at a combined price of $1.00 per unit. The transaction generated approximately $8.0 million in gross proceeds before fees and expenses. The ordinary warrants carry an exercise price of $1.15 per share, become exercisable six months post-issuance, and expire five years from the closing date. A.G.P./Alliance Global Partners served as the sole placement agent, receiving a 5.0% cash fee plus up to $50,000 in reimbursable legal expenses. The company intends to utilize net proceeds for working capital and general corporate purposes. Nano-X Imaging Ltd. operates in the medical technology industry, specializing in portable digital X-ray imaging systems.

Nano-X Imaging Ltd. announced a registered direct offering of 8,000,000 ordinary shares and warrants to purchase an additional 8,000,000 shares for gross proceeds of approximately $8 million. The securities were sold at a combined price of $1.00 per share and warrant to a single long-term institutional investor on August 5, 2026, with closing expected on August 7, 2026. Warrants carry an exercise price of $1.15 and expire five years after issuance. Concurrently, the company disclosed that it has initiated a comprehensive impairment assessment for all assets, including goodwill and long-lived assets, which remains ongoing and may result in material adjustments to its financial results for the three months ended June 30, 2026. Nano-X Imaging Ltd. operates in the medical technology industry, providing integrated digital X-ray imaging hardware, AI-based diagnostic software, and remote radiology services.

Nano-X Imaging Ltd. reported preliminary second quarter 2026 revenue of $4.0 to $4.1 million, up from $3.0 million in the prior year's corresponding period. The company's cash and cash equivalents as of June 30, 2026, are estimated at $31.4 million, down from $60.0 million at the end of 2025. Management expressed substantial doubt regarding the company's ability to continue as a going concern due to insufficient funds to support operations for at least one year. Nano-X Imaging Ltd. is a medical imaging technology company providing an integrated healthcare services platform.